A gluconolactone regimen of cleanser, toner and topical moisturizer was assessed on 25 women with sensitive skin and moderate to advanced photoaging. All parameters of photoaging were significantly (p<0.05) reduced after six and twelve weeks of twice daily use, including firmness, sallowness, fine lines, wrinkles, roughness, hyperpigmentation and pore size. Mean relative percent improvements in clinical assessments ranged from 15% for hyperpigmentation to 33% for roughness. Silicone replica analysis revealed a reduction in the appearance of fine lines and wrinkles by over 30% in twelve weeks. Significant improvements were also observed in scaling of the skin (p<0.05). The products were well tolerated by the sensitive skin panelists and any preexisting irritation was improved (p<0.05) during treatment, including erythema, tightness and tingling.*

Gluconolactone Regimen Compatible with Clinically Sensitive Skin

An open-label evaluation of the Exuviance Sensitive Skin System (cleanser, toner, moisturizers) was conducted on 30 females with acne rosacea (n=15) and atopic dermatitis (n=15). Compatibility of the test materials was determined by clinical assessments including physician global assessment and patient assessment. Following 12 weeks of twice daily use, results demonstrated compatibility with acne rosacea and atopic skin, with significant improvements (p<0.05) in skin texture, dryness, erythema and overall irritation in acne rosacea patients. Products were well tolerated on clinically sensitive skin.*

Gluconolactone Strengthens Skin Barrier Function

Following twice daily applications for four weeks of an AHA formulation (Glycolic Acid, 8% cream, pH 4.4) and PHA (Gluconolactone, 8% cream, pH 4.3) on volar forearms, treatment sites were patch-challenged with a common skin irritant Sodium Lauryl Sulfate (5%, aqueous) under occlusion for 6 hours. Barrier function of the skin was assessed during the 4 weeks of product usage and following SLS challenge (immediately, after 24 hours and after 48 hours) using Trans-Epidermal Water Loss (TEWL). Test product comparisons were made against a Vehicle (VEH) and Untreated (UNT) control.

Results indicate that skin sites treated with Gluconolactone exhibited statistically lower degrees of barrier dysfunction following SLS challenge in comparison to Glycolic Acid, vehicle and untreated sites, p<0.05. Glycolic Acid was not different from Untreated (p<0.05). British Journal of Dermatology 1997; 137: 934-938.

* data on file.